{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"MCK","limit":50},"count":50,"signals":[{"ticker":"MCK","company":"MCKESSON CORP","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"risk_factor","strength":100,"match_count":35,"context":"h Laws | 162 | | | SECTION 5.02Authorization No Contravention | 162 | | | SECTION 5.03Governmental Authorization | 162 | | | SECTION 5.04Binding Effect | 163 | | | SECTION 5.05Financial Statements No Material Adverse Effect | 163 | | | SECTION 5.06Litigation | 163 | | | SECTION 5.07Reserved | 163 | | | SECTION 5.08Ownership of Property Liens | 163 | | | SECTION 5.09Environmental Matters | 163 | | | SECTION 5.10Taxes | 1","filed_date":"2026-04-06","accession":"0000927653-26-000045","full_text":"https://origin.rootz.global/static/filing/0000927653-26-000045.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MCK","company":"MCKESSON CORP","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"restructuring","strength":100,"match_count":27,"context":"thout future economic benefits, project consulting fees, and other exit costs expensed as incurred. The following table summarizes the activity related to the liabilities associated with the Companys restructuring initiatives for the nine months ended December 31, 2025: | | | (In millions) | North American Pharmaceutical | Prescription Technology Solutions | Medical-Surgical Solutions | Corporate | Total | | | Balance, M","filed_date":"2026-02-04","accession":"0000927653-26-000017","full_text":"https://origin.rootz.global/static/filing/0000927653-26-000017.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MCK","company":"MCKESSON CORP","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"restructuring","strength":100,"match_count":25,"context":"thout future economic benefits, project consulting fees, and other exit costs expensed as incurred. The following table summarizes the activity related to the liabilities associated with the Companys restructuring initiatives for the six months ended September 30, 2025: | | | (In millions) | North American Pharmaceutical | Prescription Technology Solutions | Medical-Surgical Solutions | Corporate | Total | | | Balance, M","filed_date":"2025-11-06","accession":"0000927653-25-000140","full_text":"https://origin.rootz.global/static/filing/0000927653-25-000140.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MCK","company":"MCKESSON CORP","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"risk_factor","strength":100,"match_count":50,"context":"d to the business units revenues. Consistent with our findings in past years, management concluded that for FY 2025 our policies and practices do not create risks that are reasonably likely to have a material adverse effect on the Company. A summary of managements findings was reviewed with the Compensation and Talent Committee at its April 2025 meeting.The Compensation and Talent Committee discussed managements finding","filed_date":"2025-06-20","accession":"0000927653-25-000061","full_text":"https://origin.rootz.global/static/filing/0000927653-25-000061.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MCK","company":"MCKESSON CORP","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"strategic_event","strength":100,"match_count":25,"context":"| | | As required by Section 14A of the Securities Exchange Act of 1934, as amended (Exchange Act), shareholders are entitled to vote to approve, on a non-binding advisory basis, the compensation of named executive officers (NEOs) as disclosed in this proxy statement. This item, commonly known as a say-on-pay proposal, gives shareholders the opportunity to express their views on compensation for NEOs. The vote is not i","filed_date":"2025-06-20","accession":"0000927653-25-000061","full_text":"https://origin.rootz.global/static/filing/0000927653-25-000061.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MCK","company":"MCKESSON CORP","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"risk_factor","strength":100,"match_count":19,"context":"wnership or leasing of property or the conduct of business, except for such jurisdictions where the failure to so qualify or to be in good standing would not, individually or in the aggregate, have a material adverse effect on the condition, financial or otherwise, earnings, management, business, properties, results of operations or prospects of the Company and its subsidiaries, considered as one entity (a Material Adve","filed_date":"2025-05-30","accession":"0001628280-25-028495","full_text":"https://origin.rootz.global/static/filing/0001628280-25-028495.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MCK","company":"MCKESSON CORP","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"restructuring","strength":100,"match_count":36,"context":"Canadian retail disposal group and total operating expenses for the year ended March 31, 2025 includes fair value remeasurement charges of $667million; For the year ended March 31, 2025, we recorded restructuring charges of $298 million related to an enterprise-wide initiative to drive operational efficiencies as further described in the Restructuring Initiatives section of [Overview of Consolidated Results](#i1932fa","filed_date":"2025-05-09","accession":"0000927653-25-000036","full_text":"https://origin.rootz.global/static/filing/0000927653-25-000036.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MCK","company":"MCKESSON CORP","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"risk_factor","strength":100,"match_count":83,"context":"products, or ceasing other activities. While the outcome of any litigation or dispute is inherently uncertain, we do not believe that the resolution of any of these infringement notices would have a material adverse impact on our results of operations.  8 | | | Table of Contents | Item 1 Index | | McKESSON CORPORATION We hold inbound licenses for certain intellectual property that is used internally, and in some cases,","filed_date":"2025-05-09","accession":"0000927653-25-000036","full_text":"https://origin.rootz.global/static/filing/0000927653-25-000036.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MCK","company":"MCKESSON CORP","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"restructuring","strength":100,"match_count":26,"context":"ng, impairment, and related charges, net and $63 million was included in Cost of sales in the Condensed Consolidated Statement of Operations, for the nine months ended December 31, 2024, respectively.Restructuring InitiativesDuring the second quarter of fiscal 2025, the Company approved enterprise-wide initiatives to modernize and accelerate the technology service operating model, which are intended to improve business c","filed_date":"2025-02-06","accession":"0000927653-25-000014","full_text":"https://origin.rootz.global/static/filing/0000927653-25-000014.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MCK","company":"MCKESSON CORP","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"restructuring","strength":100,"match_count":27,"context":"d related charges, net and $63 million was included in Cost of sales in the Condensed Consolidated Statement of Operations, for each of the three and six months ended September 30, 2024, respectively.Restructuring InitiativesDuring the second quarter of fiscal 2025, the Company approved enterprise-wide initiatives to modernize and accelerate the technology service operating model, which are intended to improve business c","filed_date":"2024-11-07","accession":"0000927653-24-000125","full_text":"https://origin.rootz.global/static/filing/0000927653-24-000125.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MCK","company":"MCKESSON CORP","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"risk_factor","strength":100,"match_count":19,"context":"wnership or leasing of property or the conduct of business, except for such jurisdictions where the failure to so qualify or to be in good standing would not, individually or in the aggregate, have a material adverse effect on the condition, financial or otherwise, earnings, management, business, properties, results of operations or prospects of the Company and its subsidiaries, considered as one entity (a Material Adve","filed_date":"2024-09-10","accession":"0000927653-24-000110","full_text":"https://origin.rootz.global/static/filing/0000927653-24-000110.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MCK","company":"MCKESSON CORP","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"risk_factor","strength":100,"match_count":35,"context":"d to the business units revenues. Consistent with our findings in past years, management concluded that for FY 2024 our policies and practices do not create risks that are reasonably likely to have a material adverse effect on the Company. A summary of managements findings was reviewed with the Compensation and Talent Committee at its April 2024 meeting.The Compensation and Talent Committee discussed managements finding","filed_date":"2024-06-21","accession":"0000927653-24-000065","full_text":"https://origin.rootz.global/static/filing/0000927653-24-000065.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MCK","company":"MCKESSON CORP","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"strategic_event","strength":100,"match_count":24,"context":"| | | As required by Section 14A of the Securities Exchange Act of 1934, as amended (Exchange Act), shareholders are entitled to vote to approve, on a non-binding advisory basis, the compensation of named executive officers (NEOs) as disclosed in this proxy statement. This item, commonly known as a say-on-pay proposal, gives shareholders the opportunity to express their views on compensation for NEOs. The vote is not i","filed_date":"2024-06-21","accession":"0000927653-24-000065","full_text":"https://origin.rootz.global/static/filing/0000927653-24-000065.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MCK","company":"MCKESSON CORP","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"restructuring","strength":100,"match_count":22,"context":"previously discussed in the Trends and Uncertainties section above; and Restructuring, impairment, and related charges, net primarily includes charges related to Corporate expenses, net. Refer to the Restructuring Initiatives and Long-Lived Asset Impairments discussion below as well as Financial Note 3, Restructuring, Impairment, and Related Charges, Net, to the consolidated financial statements included in this Annual R","filed_date":"2024-05-08","accession":"0000927653-24-000035","full_text":"https://origin.rootz.global/static/filing/0000927653-24-000035.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MCK","company":"MCKESSON CORP","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"risk_factor","strength":100,"match_count":74,"context":"products, or ceasing other activities. While the outcome of any litigation or dispute is inherently uncertain, we do not believe that the resolution of any of these infringement notices would have a material adverse impact on our results of operations.  We hold inbound licenses for certain intellectual property that is used internally, and in some cases, utilized in McKessons products or services. While in the future i","filed_date":"2024-05-08","accession":"0000927653-24-000035","full_text":"https://origin.rootz.global/static/filing/0000927653-24-000035.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MCK","company":"MCKESSON CORP","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"strategic_event","strength":100,"match_count":18,"context":"tances indicating that the carrying value of our intangible and other long-lived assets may not be recoverable include slower growth rates, the loss of a significant customer, burdensome new laws, or divestiture of a business or asset for less than its carrying value. There are inherent uncertainties in managements estimates, judgments, and assumptions used in assessing recoverability of goodwill, intangibles,","filed_date":"2024-05-08","accession":"0000927653-24-000035","full_text":"https://origin.rootz.global/static/filing/0000927653-24-000035.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MCK","company":"MCKESSON CORP","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"risk_factor","strength":100,"match_count":15,"context":"wnership or leasing of property or the conduct of business, except for such jurisdictions where the failure to so qualify or to be in good standing would not, individually or in the aggregate, have a material adverse effect on the condition, financial or otherwise, earnings, management, business, properties, results of operations or prospects of the Company and its subsidiaries, considered as one entity (a Material Adve","filed_date":"2023-06-16","accession":"0001193125-23-168978","full_text":"https://origin.rootz.global/static/filing/0001193125-23-168978.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MCK","company":"MCKESSON CORP","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"risk_factor","strength":100,"match_count":14,"context":"d to the business units revenues. Consistent with our findings in past years, management concluded that for FY 2023 our policies and practices do not create risks that are reasonably likely to have a material adverse effect on the Company. A summary of managements findings was reviewed with the Compensation and Talent Committee at its April 2023 meeting.  The Compensation and Talent Committee discussed managements findi","filed_date":"2023-06-09","accession":"0001193125-23-164501","full_text":"https://origin.rootz.global/static/filing/0001193125-23-164501.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MCK","company":"MCKESSON CORP","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"strategic_event","strength":100,"match_count":27,"context":"f the Advisory Vote on Executive Compensation (see page70) |  |  ONE YEAR | | |  |  |  Shareholders may indicate whether they would prefer future non-binding advisory votes on the compensation of our named executive officers to occur every one, two or three years. | | |  |  |  |  |  | | |  |  |  | | |  5 |  |  Shareholder Proposal on Ratification of Termination Pay (see page71) |  |  AGAINST | | |  |  |  Long-term incen","filed_date":"2023-06-09","accession":"0001193125-23-164501","full_text":"https://origin.rootz.global/static/filing/0001193125-23-164501.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MCK","company":"MCKESSON CORP","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"restructuring","strength":100,"match_count":18,"context":"ties section above for further discussion; Restructuring, impairment, and related charges, net primarily includes charges related to Corporate expenses, net, as well as our RxTS segment. Refer to the Restructuring Initiatives and Long-Lived Asset Impairments section below as well as Financial Note 3, Restructuring, Impairment, and Related Charges, Net, to the consolidated financial statements included in this Annual Repo","filed_date":"2023-05-09","accession":"0000927653-23-000038","full_text":"https://origin.rootz.global/static/filing/0000927653-23-000038.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MCK","company":"MCKESSON CORP","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"risk_factor","strength":100,"match_count":34,"context":"products, or ceasing other activities. While the outcome of any litigation or dispute is inherently uncertain, we do not believe that the resolution of any of these infringement notices would have a material adverse impact on our results of operations.  We hold inbound licenses for certain intellectual property that is used internally, and in some cases, utilized in McKessons products or services. While in the future i","filed_date":"2023-05-09","accession":"0000927653-23-000038","full_text":"https://origin.rootz.global/static/filing/0000927653-23-000038.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MCK","company":"MCKESSON CORP","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"strategic_event","strength":100,"match_count":19,"context":"tances indicating that the carrying value of our intangible and other long-lived assets may not be recoverable include slower growth rates, the loss of a significant customer, burdensome new laws, or divestiture of a business or asset for less than its carrying value. There are inherent uncertainties in managements estimates, judgments, and assumptions used in assessing recoverability of goodwill, intangibles,","filed_date":"2023-05-09","accession":"0000927653-23-000038","full_text":"https://origin.rootz.global/static/filing/0000927653-23-000038.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MCK","company":"MCKESSON CORP","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"risk_factor","strength":100,"match_count":15,"context":"wnership or leasing of property or the conduct of business, except for such jurisdictions where the failure to so qualify or to be in good standing would not, individually or in the aggregate, have a material adverse effect on the condition, financial or otherwise, earnings, management, business, properties, results of operations or prospects of the Company and its subsidiaries, considered as one entity (a Material Adve","filed_date":"2023-02-15","accession":"0001193125-23-040194","full_text":"https://origin.rootz.global/static/filing/0001193125-23-040194.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MCK","company":"MCKESSON CORP","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"risk_factor","strength":100,"match_count":26,"context":"l or substantially all the assets constituting a business unit, division, product line or line of business of) any Person provided that the aggregate consideration therefor exceeds US$500,000,000. 21 Material Adverse Effect means (a)a material adverse change in, or a material adverse effect upon, the operations, business, properties or condition (financial or otherwise) of the Company and its Subsidiaries taken as a who","filed_date":"2022-11-07","accession":"0000927653-22-000100","full_text":"https://origin.rootz.global/static/filing/0000927653-22-000100.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MCK","company":"MCKESSON CORP","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"risk_factor","strength":100,"match_count":14,"context":"d to the business units revenues. Consistent with our findings in past years, management concluded that for FY 2022 our policies and practices do not create risks that are reasonably likely to have a material adverse effect on the Company. A summary of managements findings was reviewed with the Compensation Committee at its April 2022 meeting.  The Compensation Committee discussed managements findings and considered tha","filed_date":"2022-06-09","accession":"0001193125-22-171040","full_text":"https://origin.rootz.global/static/filing/0001193125-22-171040.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MCK","company":"MCKESSON CORP","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"strategic_event","strength":100,"match_count":27,"context":"rding ownership of the Companys outstanding common stock by: (i) all directors and director nominees; (ii) each executive officer named in the 2022 Summary Compensation Table below (collectively, our named executive officers or the NEOs); and (iii) all directors, NEOs and executive officers as a group. The table also includes shares of common stock that underlie outstanding RSUs and options to purchase common stock of t","filed_date":"2022-06-09","accession":"0001193125-22-171040","full_text":"https://origin.rootz.global/static/filing/0001193125-22-171040.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MCK","company":"MCKESSON CORP","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"restructuring","strength":100,"match_count":14,"context":"and more frequently if indicators for potential impairment exist. The resulting goodwill impairment charges are reflected within this line item.  Restructuring, impairment, and related charges, net: Restructuring charges that are incurred for programs in which we change our operations, the scope of a business undertaken by our business units, or the manner in which that business is conducted as well as long-lived ass","filed_date":"2022-05-09","accession":"0000927653-22-000051","full_text":"https://origin.rootz.global/static/filing/0000927653-22-000051.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MCK","company":"MCKESSON CORP","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"risk_factor","strength":100,"match_count":36,"context":"products, or ceasing other activities. While the outcome of any litigation or dispute is inherently uncertain, we do not believe that the resolution of any of these infringement notices would have a material adverse impact on our results of operations.  We hold inbound licenses for certain intellectual property that is used internally, and in some cases, utilized in McKessons products or services. While it may be neces","filed_date":"2022-05-09","accession":"0000927653-22-000051","full_text":"https://origin.rootz.global/static/filing/0000927653-22-000051.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MCK","company":"MCKESSON CORP","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"strategic_event","strength":100,"match_count":14,"context":"tics, network solutions, and technology-enabled services that deliver wide-ranging financial, operational, and clinical benefits to payers, providers and consumers. On March10, 2020, we completed the separation of our interest in the Change Healthcare JV through a split-off transaction. This transaction reduced our investment in the Change Healthcare JV to zero. Refer to Financial Note 4, Business Acquisitions","filed_date":"2022-05-09","accession":"0000927653-22-000051","full_text":"https://origin.rootz.global/static/filing/0000927653-22-000051.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MCK","company":"MCKESSON CORP","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"restructuring","strength":100,"match_count":13,"context":"September 30, 2020, respectively. These charges are included in Restructuring, impairment, and related charges in the Condensed Consolidated Statements of Operations. In addition, charges related to restructuring initiatives are included in Cost of sales in the Condensed Consolidated Statements of Operations and were not material for the three and six months ended September 30, 2021 and 2020. 11 [Table of Contents](#i61","filed_date":"2021-11-02","accession":"0000927653-21-000098","full_text":"https://origin.rootz.global/static/filing/0000927653-21-000098.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MCK","company":"MCKESSON CORP","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"risk_factor","strength":100,"match_count":15,"context":"wnership or leasing of property or the conduct of business, except for such jurisdictions where the failure to so qualify or to be in good standing would not, individually or in the aggregate, have a material adverse effect on the condition, financial or otherwise, earnings, management, business, properties, results of operations or prospects of the Company and its subsidiaries, considered as one entity (a Material Adve","filed_date":"2021-08-12","accession":"0001193125-21-244658","full_text":"https://origin.rootz.global/static/filing/0001193125-21-244658.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MCK","company":"MCKESSON CORP","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"restructuring","strength":100,"match_count":16,"context":"e 30, 2021 and 2020, respectively. These charges are included in Restructuring, impairment, and related charges in the Condensed Consolidated Statements of Operations. In addition, charges related to restructuring initiatives are included in Cost of sales in the Condensed Consolidated Statements of Operations and were not material for the three months ended June 30, 2021 and 2020. Restructuring Initiatives During the fir","filed_date":"2021-08-05","accession":"0000927653-21-000065","full_text":"https://origin.rootz.global/static/filing/0000927653-21-000065.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MCK","company":"MCKESSON CORP","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"risk_factor","strength":100,"match_count":14,"context":"d to the business units revenues. Consistent with our findings in past years, management concluded that for FY 2021 our policies and practices do not create risks that are reasonably likely to have a material adverse effect on the Company. A summary of managements findings was reviewed with the Compensation Committee at its April 2021 meeting.  The Compensation Committee discussed managements findings and considered tha","filed_date":"2021-06-08","accession":"0001193125-21-185412","full_text":"https://origin.rootz.global/static/filing/0001193125-21-185412.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MCK","company":"MCKESSON CORP","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"strategic_event","strength":100,"match_count":30,"context":"Highlights: Risk Management and Compliance  Healthcare Industry Experience |  |  |  |  Bradley E. Lerman Senior Vice President, General Counsel and Corporate Secretary of Medtronic plc Mr. Lerman was named senior vice president, general counsel and corporate secretary of Medtronic plc, a provider of medical technology, services and solutions, in May of 2014 and serves as a member of the executive committee. In this role, he","filed_date":"2021-06-08","accession":"0001193125-21-185412","full_text":"https://origin.rootz.global/static/filing/0001193125-21-185412.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MCK","company":"MCKESSON CORP","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"restructuring","strength":100,"match_count":29,"context":"arter and more frequently if indicators for potential impairment exist. The resulting goodwill impairment charges are reflected within this line item.  Restructuring, impairment, and related charges: Restructuring charges that are incurred for programs in which we change our operations, the scope of a business undertaken by our business units, or the manner in which that business is conducted as well as long-lived ass","filed_date":"2021-05-12","accession":"0000927653-21-000039","full_text":"https://origin.rootz.global/static/filing/0000927653-21-000039.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MCK","company":"MCKESSON CORP","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"risk_factor","strength":100,"match_count":37,"context":"products, or ceasing other activities. While the outcome of any litigation or dispute is inherently uncertain, we do not believe that the resolution of any of these infringement notices would have a material adverse impact on our results of operation.  8 [Table of Contents](#i08f9baf810c0412e93ea6effc6d22995_7) McKESSON CORPORATION We hold inbound licenses for certain intellectual property that is used internally, and","filed_date":"2021-05-12","accession":"0000927653-21-000039","full_text":"https://origin.rootz.global/static/filing/0000927653-21-000039.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MCK","company":"MCKESSON CORP","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"strategic_event","strength":100,"match_count":22,"context":"tics, network solutions, and technology-enabled services that deliver wide-ranging financial, operational, and clinical benefits to payers, providers and consumers. On March10, 2020, we completed the separation of our interest in the Change Healthcare JV through a split-off transaction. This transaction reduced our investment in the Change Healthcare JV to zero. Refer to Financial Note 2, Investment in Change","filed_date":"2021-05-12","accession":"0000927653-21-000039","full_text":"https://origin.rootz.global/static/filing/0000927653-21-000039.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MCK","company":"MCKESSON CORP","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"restructuring","strength":100,"match_count":20,"context":"se charges are included under the caption, Restructuring, impairment, and related charges in Operating expenses in the Condensed Consolidated Statements of Operations. In addition, charges related to restructuring initiatives are included under the caption Cost of sales in its Condensed Consolidated Statements of Operations and were not material for the three and nine months ended December 31, 2020 and 2019. Restructurin","filed_date":"2021-02-02","accession":"0000927653-21-000013","full_text":"https://origin.rootz.global/static/filing/0000927653-21-000013.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MCK","company":"MCKESSON CORP","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"risk_factor","strength":100,"match_count":15,"context":"wnership or leasing of property or the conduct of business, except for such jurisdictions where the failure to so qualify or to be in good standing would not, individually or in the aggregate, have a material adverse effect on the condition, financial or otherwise, earnings, management, business, properties, results of operations or prospects of the Company and its subsidiaries, considered as one entity (a Material Adve","filed_date":"2020-12-03","accession":"0001193125-20-309508","full_text":"https://origin.rootz.global/static/filing/0001193125-20-309508.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MCK","company":"MCKESSON CORP","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"restructuring","strength":100,"match_count":20,"context":"se charges are included under the caption, Restructuring, impairment, and related charges in Operating expenses in the Condensed Consolidated Statements of Operations. In addition, charges related to restructuring initiatives are included under the caption Cost of sales in its Condensed Consolidated Statements of Operations and were not material for the three and six months ended September 30, 2020 and 2019. Restructurin","filed_date":"2020-11-03","accession":"0000927653-20-000093","full_text":"https://origin.rootz.global/static/filing/0000927653-20-000093.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MCK","company":"MCKESSON CORP","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"risk_factor","strength":100,"match_count":16,"context":"d to the business units revenues. Consistent with our findings in past years, management concluded that for FY 2020 our policies and practices do not create risks that are reasonably likely to have a material adverse effect on the Company. A summary of managements findings was reviewed with the Compensation Committee at its April 2020 meeting.  The Compensation Committee discussed managements findings and considered tha","filed_date":"2020-06-18","accession":"0001193125-20-172462","full_text":"https://origin.rootz.global/static/filing/0001193125-20-172462.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MCK","company":"MCKESSON CORP","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"strategic_event","strength":100,"match_count":31,"context":"as its chairman, president and chief executive officer. She held the position of chair from 2007 to 2013, and previously from 1998 to 2005. She was co-chairman of the board from 1997 to 1998 and was elected president in 1992 and chief executive officer in 1993. Ms. Jacobs served as co-chair of the Securities and Exchange Commission Advisory Committee on Small and Emerging Companies from September 2011 to September 2015. Skills & Q","filed_date":"2020-06-18","accession":"0001193125-20-172462","full_text":"https://origin.rootz.global/static/filing/0001193125-20-172462.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MCK","company":"MCKESSON CORP","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"restructuring","strength":100,"match_count":16,"context":"xall Health retail business (Rexall Health) in Other (mainly customer relationships), and the remaining $156 million primarily represents employee severance and exit-related costs related to our 2019 restructuring initiatives, as further discussed below; and | | | | | | | | Total operating expenses includes higher SD&A due to our business acquisitions and to support business growth, as well as our technology initiatives,","filed_date":"2020-05-22","accession":"0000927653-20-000033","full_text":"https://origin.rootz.global/static/filing/0000927653-20-000033.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MCK","company":"MCKESSON CORP","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"risk_factor","strength":100,"match_count":29,"context":"products, or ceasing other activities. While the outcome of any litigation or dispute is inherently uncertain, we do not believe that the resolution of any of these infringement notices would have a material adverse impact on our results of operation.  We hold inbound licenses for certain intellectual property that is used internally, and in some cases, utilized in McKessons products or services. While it may be necess","filed_date":"2020-05-22","accession":"0000927653-20-000033","full_text":"https://origin.rootz.global/static/filing/0000927653-20-000033.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MCK","company":"MCKESSON CORP","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"strategic_event","strength":100,"match_count":23,"context":"for the Northern District of California, Case No. 19-cv-02869. On August 26, 2019, the plaintiff filed an amended complaint, removing all claims except for an alleged breach of fiduciary duty by the named current and former officers and directors of the Company. On January 21, 2020, the United States District Court for the Northern District of California granted the defendants motion to dismiss the complaint, and on February 20","filed_date":"2020-05-22","accession":"0000927653-20-000033","full_text":"https://origin.rootz.global/static/filing/0000927653-20-000033.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MCK","company":"MCKESSON CORP","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"risk_factor","strength":100,"match_count":19,"context":"rldwide in U.S. dollars and the functional currencies of its foreign subsidiaries, including Euro, British pound sterling and Canadian dollars. Changes in foreign currency exchange rates could have a material adverse impact on the Companys financial results that are reported in U.S. dollars. The Company is also exposed to foreign currency exchange rate risk related to its foreign subsidiaries, including intercompany loa","filed_date":"2020-02-04","accession":"0000927653-20-000016","full_text":"https://origin.rootz.global/static/filing/0000927653-20-000016.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MCK","company":"MCKESSON CORP","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"risk_factor","strength":100,"match_count":21,"context":"rldwide in U.S. dollars and the functional currencies of our foreign subsidiaries, including Euro, British pound sterling and Canadian dollars. Changes in foreign currency exchange rates could have a material adverse impact on our financial results that are reported in U.S. dollars. We are also exposed to foreign currency exchange rate risk related to our foreign subsidiaries, including intercompany loans denominated in","filed_date":"2019-10-30","accession":"0000927653-19-000021","full_text":"https://origin.rootz.global/static/filing/0000927653-19-000021.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MCK","company":"MCKESSON CORP","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"risk_factor","strength":100,"match_count":21,"context":"erbank Eurodollar market.  Margin Stock means margin stock as such term is defined in Regulation T, U or X of the FRB.  Master Agreement has the meaning set forth in the definition of Swap Contract.  Material Adverse Effect means (a) a material adverse change in, or a material adverse effect upon, the operations, business, properties or condition (financial or otherwise) of the Company and its Subsidiaries taken as a wh","filed_date":"2019-09-27","accession":"0001193125-19-257628","full_text":"https://origin.rootz.global/static/filing/0001193125-19-257628.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MCK","company":"MCKESSON CORP","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"risk_factor","strength":100,"match_count":16,"context":"rldwide in U.S. dollars and the functional currencies of our foreign subsidiaries, including Euro, British pound sterling and Canadian dollars. Changes in foreign currency exchange rates could have a material adverse impact on our financial results that are reported in U.S. dollars. We are also exposed to foreign currency exchange rate risk related to our foreign subsidiaries, including intercompany loans denominated in","filed_date":"2019-08-01","accession":"0000927653-19-000015","full_text":"https://origin.rootz.global/static/filing/0000927653-19-000015.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MCK","company":"MCKESSON CORP","exchange":"NYSE","sector":"Wholesale-Drugs, Proprietaries & Druggists' Sundries","signal_type":"strategic_event","strength":100,"match_count":27,"context":"f mind for the Board. We continue to make progress on the initiatives we launched in March 2018 to help fight the opioid epidemic. The nonprofit organization we formed to combat the opioid crisis has appointed a board chair and president, and has defined both its mission and its vision. With patients at the center, the foundation is focused on supporting programs and grants in four key areas: provider education, payer strategies, pol","filed_date":"2019-06-21","accession":"0001193125-19-178741","full_text":"https://origin.rootz.global/static/filing/0001193125-19-178741.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"4bd39af367b51630f355e0c6c2844fd959d8cbdf5ce7c77088ac003012694f5b","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"54842109c086ff8f6d3bf39c915a8bd5ea23a56601eb50c30891d377fec65008","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":400,"hourly_limit":500,"remaining":100,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}